Brand Guidelines — Azuriya Pharma
Brand Guidelines · Version 1.0

A working reference for
identity, color, type,
and voice.

Azuriya is a clinical-stage biopharmaceutical company developing APX3330 — a first-in-class oral APE1/Ref-1 inhibitor for IBD. This page codifies how the company looks and sounds, so that every deck, page, and poster lands with the same precision.

00 · Introduction

The Azuriya identity

The brand has to communicate two things at once: the precision of a serious clinical team, and the ambition of a company that thinks inflammation can be reset at its molecular thermostat. This page is the working reference for doing that consistently.

Who this is for

Anyone producing externally-facing Azuriya materials — slide decks, the website, investor one-pagers, scientific posters, contract collateral, social, and press. Follow these rules by default; deviations require CEO sign-off.

Brand pillars

  • Precise. Name the mechanism, cite the number, reference the trial. Avoid adjectives where a datum will do.
  • Reserved. We describe what has been observed in the data we have. We do not extrapolate. Hedge language — observed, supports, suggests — is appropriate in preclinical and early-clinical contexts.
  • Ambitious. A small flourish — the gradient, a single italic phrase — signals that this is not a me-too program. Used sparingly.
02 · Palette

Color

The palette is pulled directly from the logo. Three families: brand core (indigo, emerald, violet/magenta) for identity; surfaces (cloud, lavender, mint) for backgrounds; neutrals for text and lines. The color balance across any page should skew indigo-first, with emerald and the gradient used as accents rather than fields.

Brand core

Indigo
Primary
#1C1691
Pantone 2735 C
Indigo Deep
Hover
#14107A
Pantone 2736 C
Ink
Dark background
#0B0A4E
Pantone 2765 C
Emerald
Secondary
#00A03C
Pantone 355 C
Emerald Bright
Hover
#14BE54
Pantone 354 C
Violet
Gradient 0%
#8B4FD8
Pantone 2592 C
Magenta
Gradient 100%
#C850DC
Pantone 247 C
White
Base
#FFFFFF

Surfaces & neutrals

Cloud
Neutral surface
#F7F8FC
Lavender
Corporate tint
#F0EBFA
Mint
Science tint
#E6F7EC
Line
Dividers
#E4E4F0

Signature gradient

Linear, 90° (left to right): #8B4FD8 at 0% → #C850DC at 100%. Used exclusively for the italic highlight phrase in hero H1s, the active-page underline in navigation, the left-border accent on featured callouts, and a single divider element between major sections.

Contrast & accessibility

PairingSampleRatioWCAG
Indigo on White Aa 13.4 : 1 AAA (all sizes)
White on Indigo Aa 13.4 : 1 AAA (all sizes)
Ink (body) on White Aa 16.7 : 1 AAA (all sizes)
Emerald on White Aa 4.5 : 1 AA (normal text)
Violet on White Aa 4.8 : 1 Display only (≥ 24 px)
Magenta on White Aa 3.6 : 1 Large-text only
03 · Type

Typography

Two faces carry most of the identity. Fraunces, a variable serif with an optical-size axis, handles display. Manrope, a modern geometric sans, handles body. A monospace — JetBrains Mono — handles the technical spine: compound names, gene symbols, DOI / PMID, NCT numbers.

Fraunces
Display
Variable serif. Page H1 and hero H1 at 48–64 px with opsz axis set to 144, weight 600–700. Italic reserved for the gradient-highlighted phrase.
Manrope
Body
All running copy, navigation, labels, buttons, forms, tables. Weight 400 for prose, 600 for UI labels, 700 for eyebrows.
APX3330
Mono — JetBrains Mono
Compound and target names, gene/protein symbols (NF-κB, HIF-1α), DOIs, PMIDs, NCT trial IDs, code-like sub-labels.

Type scale (desktop)

display-xlFraunces64 px700line-height 1.05

Targeting the upstream cause.

display-lgFraunces48 px700line-height 1.1

A thermostat for inflammation.

display-mdFraunces36 px600line-height 1.15

Mechanism, not a moment.

headingManrope24 px600line-height 1.3

Pipeline & patents through 2044+

subheadManrope20 px600line-height 1.35

Four master transcription factors

body-lgManrope18 px400line-height 1.55

APX3330 is a late-stage, first-in-class oral small-molecule therapy that modulates APE1/Ref-1 — the master transcription-factor regulator controlling NF-κB, HIF-1α, STAT3, and AP-1.

bodyManrope16 px400line-height 1.6

Safety across four trials in ~400 patients, 600 mg RP2D, zero treatment-related SAEs observed. Composition-of-matter and method-of-use protection through 2044+ across seven patent families.

labelManrope13 px700uppercase · track 0.08em

Phase 2a · Australia · 2026

monoJetBrains Mono14 px500line-height 1.5

APX3330 · APE1/Ref-1 · NCT03375086 · DOI 10.1038/s42003-026-09860-z

Mobile & fallbacks

On mobile, display sizes scale down: display-xl → 40 px, display-lg → 32 px, display-md → 26 px; body stays at 15 px with line-heights loosened by +0.05. Web-safe fallbacks if the primary family fails to load: Fraunces → Georgia → serif, Manrope → system-ui → sans-serif, JetBrains Mono → SF Mono → Menlo → monospace.

04 · Tone

Voice & messaging

The Azuriya voice is that of a clinical team that respects its audience. It does not oversell. It does not hedge when it has data. It uses the specific word (mechanism, pathway, master regulator) rather than the comforting one (approach, target, key factor).

Write this way

  • Specific numbers beat adjectives. "~400 patients dosed across four trials" is better than "extensively studied." "2044+ patent life" is better than "long patent runway."
  • Mechanism first. Lead with APE1/Ref-1 inhibition and the four master transcription factors (NF-κB, HIF-1α, STAT3, AP-1). Don't lead with "novel" or "first-in-class" as abstract claims.
  • Active voice, short clauses. "APX3330 inhibits APE1/Ref-1" — not "APE1/Ref-1 is inhibited by APX3330 via a redox-regulatory mechanism involving…"
  • Name the trial. NCT03375086, ZETA-1, Phase 1 HV (Eisai). Numbers and identifiers are citable.

Approved positioning vs. avoid

✓ Approved positioning

First-in-class oral APE1/Ref-1 inhibitor for inflammatory bowel disease.

Upstream of the four master transcription factors that drive IBD inflammation.

~400 patients dosed across prior clinical studies; 600 mg RP2D; no treatment-related SAEs observed.

Composition-of-matter and method-of-use protection through 2044+ across seven patent families.

✕ Avoid in external copy

"Cure for IBD" · "Guaranteed safety profile" · "Revolutionary" · "Game-changing"

"Better than [branded competitor]" without a direct head-to-head or a clear denominator.

"Platform" applied to a single compound.

Any efficacy claim in UC patients prior to Phase 2a data. Specific deal-value figures for comparables pulled from non-public sources.

05 · Digital & Print

Applications

A small set of canonical applications. The reference HTML templates on this site are the source of truth for any digital application — when in doubt, match the page.

Website

Primary application; reference HTML templates are the source of truth for tokens and components.

  • Hero sections use the ink→indigo gradient background.
  • All other sections use white or cloud.
  • Navigation is sticky with a blurred backdrop; active-page indicator is a 2-px gradient underline.

Slide decks

Deck template follows the same tokens as the site.

  • Title slides: ink background with knockout logo.
  • Body slides: white background, indigo H1 in Fraunces 36 pt, Manrope body 18 pt.
  • Data slides: tables use indigo header rows; body rows alternate white and cloud.

Investor materials

  • One-pagers use the lavender-tinted card layout with indigo H1 and emerald accent numerics.
  • Financials and market sizing shown as mono-typeset values in JetBrains Mono for typographic distinction.
  • Safe-harbor / forward-looking disclaimer set in Manrope 9 pt at the foot of every page.

Print & social

  • Business cards: 3.5 × 2 in, indigo reverse with knockout logo on front; white with full-color logo on back.
  • Letterhead: logo top-left with 1 in margin; footer with a single indigo 1-pt rule above the address.
  • Social avatars: isolated emerald arc on indigo square, 400 × 400 px.

Email signature

Standardized signature block for all @azuriyapharma.com addresses:

Firstname Lastname
Title · Azuriya Pharma
[email protected] · azuriyapharma.com
Developing APX3330 — a first-in-class oral APE1/Ref-1 inhibitor for IBD.
06 · Reference

Design tokens

CSS custom properties published in styles.css. These are the canonical values — anything produced for Azuriya should match.

TokenValueNotes
--indigo#1C1691Primary
--indigo-deep#14107AHover / pressed
--ink#0B0A4EDark backgrounds
--emerald#00A03CSecondary accent
--emerald-bright#14BE54Hover highlight
--violet#8B4FD8Gradient start
--magenta#C850DCGradient end
--cloud#F7F8FCNeutral surface
--lavender#F0EBFACorporate tint
--mint#E6F7ECScience tint
--ink-body#1A1A2EBody text
--ink-muted#555566Secondary text
--line#E4E4F0Dividers / borders
--f-displayFraunces, Georgia, serifDisplay face
--f-sansManrope, system-ui, sans-serifBody face
--f-monoJetBrains Mono, SF Mono, monospaceTechnical face
--gradient-accentlinear-gradient(90deg, #8B4FD8, #C850DC)Signature gradient
Questions, requests, deviations

Contact [email protected] for approvals on any application outside this guide. Brand updates to this document are logged with version number and date.